Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain
Open Access
- 25 June 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6), e67680
- https://doi.org/10.1371/journal.pone.0067680
Abstract
Adeno-associated virus (AAV) mediated gene expression is a powerful tool for gene therapy and preclinical studies. A comprehensive analysis of CNS cell type tropism, expression levels and biodistribution of different capsid serotypes has not yet been undertaken in neonatal rodents. Our previous studies show that intracerebroventricular injection with AAV2/1 on neonatal day P0 results in widespread CNS expression but the biodistribution is limited if injected beyond neonatal day P1. To extend these observations we explored the effect of timing of injection on tropism and biodistribution of six commonly used pseudotyped AAVs delivered in the cerebral ventricles of neonatal mice. We demonstrate that AAV2/8 and 2/9 resulted in the most widespread biodistribution in the brain. Most serotypes showed varying biodistribution depending on the day of injection. Injection on neonatal day P0 resulted in mostly neuronal transduction, whereas administration in later periods of development (24–84 hours postnatal) resulted in more non-neuronal transduction. AAV2/5 showed widespread transduction of astrocytes irrespective of the time of injection. None of the serotypes tested showed any microglial transduction. This study demonstrates that both capsid serotype and timing of injection influence the regional and cell-type distribution of AAV in neonatal rodents, and emphasizes the utility of pseudotyped AAV vectors for translational gene therapy paradigms.Keywords
This publication has 40 references indexed in Scilit:
- The AAV Vector Toolkit: Poised at the Clinical CrossroadsMolecular Therapy, 2012
- Adeno-Associated Virus (AAV) Vectors in the CNS.Current Gene Therapy, 2011
- Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regenerationGene Therapy, 2011
- Safety and tolerability of putaminal AADC gene therapy for Parkinson diseaseNeurology, 2009
- Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's DiseaseJournal of Neuroscience, 2009
- Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNAHuman Gene Therapy, 2008
- Partial Correction of Sensitivity to Oxidant Stress in Friedreich Ataxia Patient Fibroblasts by Frataxin-Encoding Adeno-Associated Virus and Lentivirus VectorsHuman Gene Therapy, 2005
- AAV-Mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophyMolecular Therapy, 2005
- Intraventricular Brain Injection of Adeno-Associated Virus Type 1 (AAV1) in Neonatal Mice Results in Complementary Patterns of Neuronal Transduction to AAV2 and Total Long-Term Correction of Storage Lesions in the Brains of β-Glucuronidase-Deficient MiceJournal of Virology, 2003
- Adeno-associated viruses undergo substantial evolution in primates during natural infectionsProceedings of the National Academy of Sciences of the United States of America, 2003